Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine

PHASE4CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

May 1, 2013

Primary Completion Date

October 1, 2016

Study Completion Date

December 30, 2016

Conditions
Neuromuscular BlockadeSugammadexNeostigmineComplication of AnesthesiaPostoperative Residual CurarizationRocuronium
Interventions
DRUG

Neostigmine

"The study investigators administer neostigmine at the end of operation to reverse neuromuscular blockade, and the routine dose of the intravenous neostigmine is 0.05 mg/kg and atropine 0.02 mg/kg. The dose is given in a single syringe, and later they administer this reversal medication before extubation.~In the case of a residual block, the neostigmine group of patients receives a rescue dose of neostigmine at a dose of 0.03 mg/kg in the operating room fifteen minutes before discharge."

DRUG

Sugammadex

The study investigators administer the routine full-dose neostigmine reversal medication and three minutes later, they administer an intravenous bolus dose of 1 mg/kg sugammadex in a different syringe prepared earlier as a reversal agent. The anesthesia team considers using an intravenous rescue dose of 1 mg/kg sugammadex for this group of patients in the recovery room if patients do not show a complete recovery of TOF ratio equal to \>0.9 in the recovery room before discharge to the ward.

All Listed Sponsors
lead

Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

OTHER_GOV

NCT05066035 - Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine | Biotech Hunter | Biotech Hunter